Eyeworld

3 EW ASCRS NEWS by Liz Hillman EyeWorld Staff Writer Clinical Survey gives members a voice in ASCRS education November 2017 barriers to adopting new technolo- gies or techniques. Gaining a better understanding of the barriers helps ASCRS understand if they can be Results from the survey provide benchmarking opportunities, identify areas of educational need, and spur discussion T he ASCRS Clinical Survey reached its 5-year milestone at the ASCRS•ASOA Sym- posium & Congress in Los Angeles in May, garnering 1,131 unique physician responses that provide insights on member- ship opinions, practice patterns, and now, with several years of data, trends. Since the survey was initiated, Rosa Braga-Mele, MD, chair, ASCRS Education Committee, said, "it has been an ever-changing landscape, adding new questions depending on member needs, industry innovation, and development." Over the years, the ASCRS Clinical Survey has been integral in directing ASCRS educa- tional program development at the annual meeting, other ASCRS meet- ings, EyeWorld events, online, and in print media. Dr. Braga-Mele said the survey is also vital to help tailor education for young ophthalmolo- gist members. The ultimate goal of directing ASCRS education based on the results of the Clinical Survey is to help create more confident, skilled surgeons and thus result in improved patient care. "The ASCRS Clinical Survey has a far-reaching effect on the overall membership experience," said Bonnie Henderson, MD, presi- dent of ASCRS. "It's ASCRS' way of developing educational content to meet specific needs and gaps as reported by members. Each year, the Clinical Committees and program- ming teams use the survey results as a guide for everything from annual meeting sessions to online educa- tion, webinars, and general report- ing. I encourage all ASCRS members to use the Clinical Survey as a way to directly shape future ASCRS educational content and, in turn, improve the value of their individu- al membership experience." Detailed questions to gather data from both U.S. and non-U.S. member ophthalmologists cover topics like cataract surgery, astig- matism management, surgical presbyopia correction, laser-assist- ed cataract surgery, ocular surface, crosslinking, corneal transplants, inflammation and infection control, corneal refractive surgery, glaucoma, and retina. Each year, volunteers from the ASCRS Clinical Commit- tees review the Clinical Survey to refine the previous year's questions or add new ones to keep the survey current. In the 2017 survey, for ex- ample, nearly 85% of the questions were new, modified, or changed. Over the years, ASCRS has not only added questions that are timely and important for analysis, such as questions about hemorrhagic occlusive retinal vasculitis (HORV) and simultaneous bilateral cataract surgery, but it has refined questions to obtain more clarity about certain continued on page 8 IMPORTANT PRODUCT INFORMATION FOR THE ACRYSOF ® IQ RESTOR ® FAMILY OF IOLs CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician. INDICATIONS: The AcrySof® IQ ReSTOR® Posterior Chamber Intra- ocular Multifocal IOLs include AcrySof® IQ ReSTOR® and AcrySof® IQ ReSTOR® Toric and are intended for primary implantation for the visual correction of aphakia secondary to removal of a cataractous lens in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle indepen- dence. In addition, the AcrySof® IQ ReSTOR® Toric IOL is intended to correct pre-existing astigmatism. The lenses are intended to be placed in the capsular bag. WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling for each IOL. Physicians should target emmetropia, and ensure that IOL centration is achieved. Care should be taken to remove viscoelastic from the eye at the close of surgery. The ReSTOR Toric IOL should not be implanted if the posterior cap- sule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation. Some patients may experience visual disturbances and/or discom- fort due to multifocality, especially under dim light conditions. A reduction in contrast sensitivity may occur in low light conditions. Visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. Spectacle independence rates vary; some patients may need glasses when reading small print or looking at small objects. Posterior capsule opacification (PCO), when present, may develop earlier into clinically significant PCO with multifocal IOLs. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefits associated with the AcrySof® IQ ReSTOR® IOLs. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS® or BSS PLUS® Sterile Intraocular Irrigating Solutions. ATTENTION: Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings and precautions. © 2017 Novartis 6/17 US-RES-17-E-1590 Clinical Committee volunteers for the 2017 ASCRS Clinical Survey • Rosa Braga-Mele, MD: All sections • Kendall Donaldson, MD: Presbyopia section • Sumit "Sam" Garg, MD: YES section • Terry Kim, MD: Cornea section • Nick Mamalis, MD: Inflammation and Infection section • Edward Manche, MD: Refractive Surgery section • Kevin Miller, MD: Retina section • Thomas Oetting, MD: Cataract Surgery section • Thomas Samuelson, MD: Glaucoma section • John Vukich, MD: Astigmatism section • Robert Weinstock, MD: FLACS section

• Blank Page
• Blank Page (1)